for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Inflarx NV

IFRX.OQ

Latest Trade

5.09USD

Change

0.12(+2.41%)

Volume

50,679

Today's Range

4.99

 - 

5.09

52 Week Range

2.17

 - 

9.68

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Inflarx Reports Qtrly Loss Per Share Eur 0.38

July 30 (Reuters) - Inflarx NV <IF0G.DE>::INFLARX REPORTS Q2 2020 FINANCIAL & OPERATING RESULTS.INFLARX NV - QTRLY LOSS PER SHARE EUR 0.38.INFLARX NV - ON JUNE 30, 2020, COMPANY'S TOTAL FUNDS AVAILABLE WERE APPROXIMATELY EUR 98.9 MILLION.

Inflarx NV Files For Mixed Shelf Of Upto $200 Million

July 8 (Reuters) - Inflarx NV <IF0G.DE>::INFLARX NV FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.

Inflarx NV Reports Q1 Loss Per Share Of EUR 0.32

May 21 (Reuters) - Inflarx NV <IF0G.DE>::INFLARX REPORTS Q1 2020 FINANCIAL & OPERATING RESULTS.Q1 LOSS PER SHARE EUR 0.32.PART 1 OF ADAPTIVE RANDOMIZED TRIAL IN SEVERE COVID-19 PNEUMONIA FULLY ENROLLED.CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS OF APPROXIMATELY EUR 108.0 MILLION AS OF MARCH 31, 2020.

Inflarx Doses First Patient In Multicenter Randomized Clinical Trial In Severe Progressed COVID-19 Pneumonia In Europe Upon Receipt Of Initial Positive Human Data With Inflarx’S Anti-C5a Technol

March 31 (Reuters) - Inflarx NV <IF0G.DE>::INFLARX DOSES FIRST PATIENT IN MULTICENTER RANDOMIZED CLINICAL TRIAL IN SEVERE PROGRESSED COVID-19 PNEUMONIA IN EUROPE UPON RECEIPT OF INITIAL POSITIVE HUMAN DATA WITH INFLARX’S ANTI-C5A TECHNOLOGY.INFLARX NV - GOT INITIAL POSITIVE HUMAN DATA FROM LICENSEE, BEIJING DEFENGREI BIOTECHNOLOGY CO. LTD SUGGESTING POTENTIAL ROLE OF C5A IN COVID-19.INFLARX NV - DECIDED TO INITIATE A CLINICAL DEVELOPMENT PROGRAM WITH IFX-1 IN COVID-19 PATIENTS WITH SEVERELY PROGRESSED PNEUMONIA.INFLARX NV - GOT INITIAL POSITIVE HUMAN DATA FROM 2 INITIAL PATIENTS SUFFERING FROM COVID-19-INDUCED SEVERE PNEUMONIA WHO WERE TREATED WITH BDB-001.

Inflarx Reports Cash And Cash Equivalents Plus Securities And Other Investments Of EUR 138.3 Million As Of June 30

Aug 14 (Reuters) - Inflarx NV <IF0G.F>::INFLARX REPORTS SECOND QUARTER 2019 FINANCIAL & OPERATING RESULTS.CASH AND CASH EQUIVALENTS PLUS SECURITIES AND OTHER INVESTMENTS OF EUR 138.3 MILLION AS OF JUNE 30, 2019.H1 LOSS PER SHARE EUR 0.97.Q2 EARNINGS PER SHARE VIEW EUR -0.47 -- REFINITIV IBES DATA.

InflaRx Reports Additional Analysis Of The SHINE Phase IIb Results For IFX-1 In Hidradenitis Suppurativa

July 18 (Reuters) - Inflarx NV <IF0G.F>::INFLARX REPORTS ADDITIONAL ANALYSIS OF THE SHINE PHASE IIB RESULTS FOR IFX-1 IN HIDRADENITIS SUPPURATIVA.INFLARX NV - IFX-1 TREATMENT IN HIGH DOSE GROUP RESULTED IN MULTIPLE EFFICACY SIGNALS SUPPORTING FURTHER DEVELOPMENT OF IFX-1 IN HS.INFLARX NV - IFX-1 SUPPRESSED C5A LEVELS DOSE DEPENDENTLY AND EXHIBITED A FAVORABLE SAFETY PROFILE WITH LOW ANTI-DRUG ANTIBODY RATES.INFLARX NV - OPEN-LABEL EXTENSION STUDY IS ONGOING, INFLARX PLANS END OF PHASE II REGULATORY DISCUSSIONS AFTER COMPLETION OF SHINE TRIAL.

Inflarx NV Files For Potential Mixed Shelf Offering; Size Not Disclosed

March 28 (Reuters) - Inflarx NV <IFRX.O>::INFLARX NV FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.

Inflarx NV Had Cash & Cash Equivalents & Securities & Other Investments Of EUR 156.6 Mln As Of Dec. 31, 2018

March 28 (Reuters) - Inflarx NV <IFRX.O>::INFLARX FULL YEAR 2018 FINANCIAL & OPERATING RESULTS.INFLARX NV - AS OF DECEMBER 31, 2018, INFLARX HAD CASH AND CASH EQUIVALENTS AND SECURITIES AND OTHER INVESTMENTS OF EUR 156.6 MILLION.

Inflarx Announces Presentation Of New Clinical Data With Lead Candidate Ifx-1 In Hidradenitis Suppurativa

Feb 6 (Reuters) - Inflarx NV <IFRX.O>::INFLARX ANNOUNCES PRESENTATION OF NEW CLINICAL DATA WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA.INFLARX NV - RETROSPECTIVE LONG-TERM RESULTS FROM PHASE IIA TRIAL INDICATE SUSTAINED REMISSION POST IFX-1 TREATMENT.INFLARX NV - BASELINE CHARACTERISTICS FROM ONGOING PHASE IIB SHINE TRIAL IN LINE WITH EXPECTATIONS; ON TRACK FOR TOPLINE RESULTS Q2 2019.

Inflarx N.V. Reports Third Quarter 2018 Financial & Operating Results

Nov 21 (Reuters) - Inflarx NV <IFRX.O>::INFLARX N.V. REPORTS THIRD QUARTER 2018 FINANCIAL & OPERATING RESULTS.Q3 LOSS PER SHARE EUR 0.30.Q3 EARNINGS PER SHARE VIEW EUR -0.36 -- THOMSON REUTERS I/B/E/S.AS OF SEPTEMBER 30, 2018, COMPANY HAD CASH AND CASH EQUIVALENTS AND SECURITIES AND OTHER INVESTMENTS OF EUR 162.1 MILLION.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up